Ranitidine Accord 300 mg filmom obalené tablety Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ranitidine accord 300 mg filmom obalené tablety

accord healthcare polska sp. z o.o., poľsko - ranitidín - 09 - antacida (vrÁtane antiulcerosnych lieČiv)

Allospes 300 mg tablety Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

allospes 300 mg tablety

accord healthcare polska sp. z o.o., poľsko - alopurinol - 29 - antirheumatica, antiphlogistica, antiuratica

Allospes 100 mg tablety Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

allospes 100 mg tablety

accord healthcare polska sp. z o.o., poľsko - alopurinol - 29 - antirheumatica, antiphlogistica, antiuratica

Epivir Európska únia - slovenčina - EMA (European Medicines Agency)

epivir

viiv healthcare bv - lamivudín - hiv infekcie - antivirotiká na systémové použitie - epivir je indikovaný ako súčasť kombinovanej antiretrovírusovej liečby ľudskej imunodeficiencie (hiv)-dospelých a detí infikovaných.

Lamivudine Teva Pharma B.V. Európska únia - slovenčina - EMA (European Medicines Agency)

lamivudine teva pharma b.v.

teva b.v.  - lamivudín - hiv infekcie - antivirotiká na systémové použitie - lamivudin teva pharma b. je indikovaná ako súčasť antiretrovírusovej kombinovanej liečby na liečbu dospelých a detí infikovaných vírusom ľudskej imunodeficiencie (hiv).

Vidaza Európska únia - slovenčina - EMA (European Medicines Agency)

vidaza

bristol-myers squibb pharma eeig - azacitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastické činidlá - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Azacitidine Celgene Európska únia - slovenčina - EMA (European Medicines Agency)

azacitidine celgene

celgene europe bv - azacitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastické činidlá - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.